MS. DEIDRA A VEACH ARNP
Prescription History 1023536265
Nurse Practitioner in Ankeny, IA

NPI Status: Active since September 08, 2017

Contact Information

1950 SW MAGAZINE RD
ANKENY, IA
ZIP 50023
Phone: (515) 282-2921
Fax: (515) 283-1035

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. DEIDRA A VEACH ARNP, an active Nurse Practitioner specialist practicing in Ankeny, IA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 127 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 62 claims alone.

Medication Index

No matching medications currently found on file.

Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 23.2
Days Supply 672
IA State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills106.5
Peer Average Days Supply3,149
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.3% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $82.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.18

State Avg Cost Per Claim

$9.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 62
30-Day Fills 124.0
Days Supply 3,713
IA State Average Benchmarks
Peer Average Claims85.0
Peer Average 30-Day Fills182.0
Peer Average Days Supply5,419
Conservative Utilization

This provider writes prescriptions for this formulation 27.1% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,088.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.56

State Avg Cost Per Claim

$22.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Eliquis

Generic Formulation: ApixabanSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
IA State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills115.0
Peer Average Days Supply3,166
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 85.2% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,155.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$596.29

State Avg Cost Per Claim

$720.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Letrozole

Generic Formulation: LetrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 23.0
Days Supply 690
IA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills115.4
Peer Average Days Supply3,441
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.6% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $273.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.86

State Avg Cost Per Claim

$21.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Morphine Sulfate Er

Generic Formulation: Morphine SulfateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 780
IA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.2
Peer Average Days Supply864
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $975.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$37.51

State Avg Cost Per Claim

$43.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.

Therapeutic Applications

This medication is used to treat severe pain. Morphine belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. DEIDRA A VEACH ARNP provides transparency into local medical care patterns within Ankeny, IA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.